Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (7325)	1/23/2004 12:33:02 PM
From: Biomaven	Read Replies (1) \| Respond to of 10280

<arformoterol plus steroid> Yes - something similar to budesonide plus arformoterol. content.nejm.org AZN has a product like this approved in Europe. Don't know if it's available in the US yet. In the US, Glaxo has Advair - a somewhat similar combo. I'm sure SEPR is aware of the potential of this combo. They couldn't use budesonide itself as it's still under patent. But they could use the steroid part of Glaxo version (Flovent) as it's losing patent protection this year. (I note that in the latest pipeline discussion SEPR talks about a steroid targeted at asthma, but that's along way off yet). This site has a little more on this combo: dresources.com Peter